



Clinical trial results:

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, WITHIN-SUBJECT, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06473871 IN REDUCING HYPERTROPHIC SKIN SCARRING

Summary

EudraCT number	2012-004355-37
Trial protocol	DE HU ES NL
Global end of trial date	07 May 2014

Results information

Result version number	v1 (current)
This version publication date	17 April 2016
First version publication date	17 April 2016

Trial information

Trial identification

Sponsor protocol code	B5301001
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01730339
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Pfizer, Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer Call Center,, Pfizer Inc, 001 800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer Call Center, Pfizer Inc, 001 800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	29 May 2015
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	07 May 2014
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate the efficacy of PF-06473871 compared to placebo, in reducing the severity of skin scarring in subjects undergoing an elective revision of hypertrophic scars resulting from prior breast surgery.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	11 December 2012
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	3 Months
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Germany: 5
Country: Number of subjects enrolled	Spain: 2
Country: Number of subjects enrolled	United States: 93
Worldwide total number of subjects	100
EEA total number of subjects	7

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0

Adults (18-64 years)	100
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

A total of 103 subjects were randomized into the study. Of these, 100 subjects received at least 1 dose of study drug and were included in the modified intent to treat (mITT) and safety population.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Subject

Arms

Are arms mutually exclusive?	Yes
Arm title	PF-06473871/Placebo (4* 5 mg/cm)

Arm description:

Subjects with bilateral hypertrophic scars received 4 intradermal injections of PF-06473871 at a dose of 5 milligram per linear centimeter (mg/cm) (2.5 mg on each side of the revised scar) on one breast at Week 2, 5, 8 and 11; and 4 intradermal injections of placebo matched to PF-06473871 at Week 2, 5, 8 and 11 on another breast.

Arm type	Experimental
Investigational medicinal product name	PF-06473871
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intradermal use

Dosage and administration details:

Subjects received 4 intradermal injections of PF-06473871 at a dose of 5 milligram per linear centimeter (mg/cm) (2.5 mg on each side of the revised scar) on one breast at Week 2, 5, 8 and 11.

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intradermal use

Dosage and administration details:

Subjects received 4 intradermal injections of placebo matched to PF-06473871 at Week 2, 5, 8 and 11 on another breast.

Arm title	PF-06473871/Placebo (3* 5 mg/cm)
------------------	----------------------------------

Arm description:

Subjects with bilateral hypertrophic scars received 3 intradermal injections of PF-06473871 at a dose of 5 milligrams per linear centimeter (mg/cm) (2.5 mg on each side of the revised scar) on one breast at Week 2, 5 and 8; and 3 intradermal injections of placebo matched to PF-06473871 at Week 2, 5 and 8 on another breast.

Arm type	Experimental
Investigational medicinal product name	PF-06473871
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intradermal use

Dosage and administration details:

Subjects received 3 intradermal injections of PF-06473871 at a dose of 5 mg/cm (2.5 mg on each side of the revised scar) on one breast at Week 2, 5 and 8.

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intradermal use

Dosage and administration details:

Subjects received 3 intradermal injections of placebo matched to PF-06473871 at Week 2, 5 and 8 on another breast.

Number of subjects in period 1	PF-06473871/Placebo (4* 5 mg/cm)	PF-06473871/Placebo (3* 5 mg/cm)
Started	45	55
Completed	40	52
Not completed	5	3
Consent withdrawn by subject	3	2
Un-specified	1	-
Lost to follow-up	1	1

Baseline characteristics

Reporting groups

Reporting group title	PF-06473871/Placebo (4* 5 mg/cm)
-----------------------	----------------------------------

Reporting group description:

Subjects with bilateral hypertrophic scars received 4 intradermal injections of PF-06473871 at a dose of 5 milligram per linear centimeter (mg/cm) (2.5 mg on each side of the revised scar) on one breast at Week 2, 5, 8 and 11; and 4 intradermal injections of placebo matched to PF-06473871 at Week 2, 5, 8 and 11 on another breast.

Reporting group title	PF-06473871/Placebo (3* 5 mg/cm)
-----------------------	----------------------------------

Reporting group description:

Subjects with bilateral hypertrophic scars received 3 intradermal injections of PF-06473871 at a dose of 5 milligrams per linear centimeter (mg/cm) (2.5 mg on each side of the revised scar) on one breast at Week 2, 5 and 8; and 3 intradermal injections of placebo matched to PF-06473871 at Week 2, 5 and 8 on another breast.

Reporting group values	PF-06473871/Placebo (4* 5 mg/cm)	PF-06473871/Placebo (3* 5 mg/cm)	Total
Number of subjects	45	55	100
Age categorical Units: Subjects			

Age Continuous Units: years arithmetic mean standard deviation	38.2 ± 8.55	37.6 ± 9.64	-
---	----------------	----------------	---

Gender, Male/Female Units: participants			
Female	44	53	97
Male	1	2	3

Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	3	0	3
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	27	39	66
White	13	16	29
More than one race	0	0	0
Unknown or Not Reported	2	0	2

Study Specific Characteristic			
Physician global assessment was performed using the overall opinion question of the POSAS scale. Physicians were asked to rate the severity of the subject's scar compared to normal skin. The overall opinion scale score ranged from 1 (normal skin) to 10 (worst imaginable scar).			

Units: units on scale arithmetic mean standard deviation	6.62 ± 1.545	6.88 ± 1.277	-
--	-----------------	-----------------	---

Study Specific Characteristic			
Subject global assessment was performed using the overall opinion question of the POSAS scale. Subjects were asked to rate the severity of their scar compared to normal skin. The overall opinion scale score ranged from 1 (normal skin) to 10 (very different from normal skin).			

Units: units on scale			
-----------------------	--	--	--

arithmetic mean	9	8.49	
standard deviation	± 1.219	± 1.617	-
Study Specific Characteristic			
Physician rated severity of each scar using a photonumeric guide on a scale ranging from 1 to 5 (where 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, 5 = very severe). Within subject treatment difference was assessed between the treatment regimens each subject received.			
Units: units on scale			
arithmetic mean	3.97	3.98	
standard deviation	± 0.682	± 0.725	-
Study Specific Characteristic			
Subjects rated severity of each scar using a photonumeric guide on a scale ranging from 1 to 5 (where 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, 5 = very severe). Within subject treatment difference was assessed between the treatment regimens each subject received.			
Units: units on scale			
arithmetic mean	4.24	4.28	
standard deviation	± 0.648	± 0.637	-

End points

End points reporting groups

Reporting group title	PF-06473871/Placebo (4* 5 mg/cm)
Reporting group description: Subjects with bilateral hypertrophic scars received 4 intradermal injections of PF-06473871 at a dose of 5 milligram per linear centimeter (mg/cm) (2.5 mg on each side of the revised scar) on one breast at Week 2, 5, 8 and 11; and 4 intradermal injections of placebo matched to PF-06473871 at Week 2, 5, 8 and 11 on another breast.	
Reporting group title	PF-06473871/Placebo (3* 5 mg/cm)
Reporting group description: Subjects with bilateral hypertrophic scars received 3 intradermal injections of PF-06473871 at a dose of 5 milligrams per linear centimeter (mg/cm) (2.5 mg on each side of the revised scar) on one breast at Week 2, 5 and 8; and 3 intradermal injections of placebo matched to PF-06473871 at Week 2, 5 and 8 on another breast.	
Subject analysis set title	Group 1: PF-06473871: (4* 5 mg/cm)
Subject analysis set type	Modified intention-to-treat
Subject analysis set description: Subjects with bilateral hypertrophic scars received 4 intradermal injections of PF-06473871 at a dose of 5 mg/cm (2.5 mg on each side of the revised scar) on one breast at Week 2, 5, 8, and 11.	
Subject analysis set title	Group 1: Placebo 4* 5 mg/cm
Subject analysis set type	Modified intention-to-treat
Subject analysis set description: Subjects who received 4 intradermal injections of PF-06473871 on one breast and 4 intradermal injections of placebo matched to PF-06473871 at Week 2, 5, 8, and 11 on another breast	
Subject analysis set title	Group 2: PF-06473871: (3* 5 mg/cm)
Subject analysis set type	Modified intention-to-treat
Subject analysis set description: Subjects with bilateral hypertrophic scars received 3 intradermal injections of PF-06473871 at a dose of 5 mg/cm (2.5 mg on each side of the revised scar) on one breast at Week 2, 5, and 8.	
Subject analysis set title	Group 2: Placebo 3* 5 mg/cm
Subject analysis set type	Modified intention-to-treat
Subject analysis set description: Subjects who received 3 intradermal injections of PF-06473871 on one breast, also received 3 intradermal injections of placebo matched to PF-06473871 at Week 2, 5, and 8 on another breast.	
Subject analysis set title	Group 1: Placebo 4* 5 mg/cm
Subject analysis set type	Modified intention-to-treat
Subject analysis set description: Subjects who received 4 intradermal injections of PF-06473871 on one breast, and 4 intradermal injections of placebo matched to PF-06473871 at Week 2, 5, 8, and 11 on another breast.	
Subject analysis set title	Group 2: Placebo 3* 5 mg/cm
Subject analysis set type	Modified intention-to-treat
Subject analysis set description: Subjects who received 3 intradermal injections of PF-06473871 on one breast, and 3 intradermal injections of placebo matched to PF-06473871 at Week 2, 5, and 8 on another breast.	
Subject analysis set title	PF-06473871/Placebo (4* 5 mg/cm)
Subject analysis set type	Modified intention-to-treat
Subject analysis set description: Subjects with bilateral hypertrophic scars received 4 intradermal injections of PF-06473871 at a dose of 5 mg/cm, (2.5 mg on each side of the revised scar) on one breast at Week 2, 5, 8 and 11; and 4 intradermal injections of placebo matched to PF-06473871 at Week 2, 5, 8 and 11 on another breast.	
Subject analysis set title	PF-06473871/Placebo (4* 5 mg/cm)
Subject analysis set type	Modified intention-to-treat
Subject analysis set description: Subjects with bilateral hypertrophic scars received 4 intradermal injections of PF-06473871 at a dose of	

5 mg/cm (2.5 mg on each side of the revised scar) on one breast at Week 2, 5, 8 and 11; and 4 intradermal injections of placebo matched to PF-06473871 at Week 2, 5, 8 and 11 on another breast.

Primary: Physician Global Assessment Using Physician Overall Opinion Question of Patient and Observer Scar Assessment Scale (POSAS)

End point title	Physician Global Assessment Using Physician Overall Opinion Question of Patient and Observer Scar Assessment Scale (POSAS)
-----------------	--

End point description:

Physician global assessment was performed using the overall opinion question of the POSAS scale. Physicians were asked to rate the severity of the subjects scar compared to normal skin. The overall opinion scale score ranged from 1 (normal skin) to 10 (worst imaginable scar). Within subject treatment difference was assessed between the treatment regimens each subject received. Modified Intent To Treat (mITT) population included all subjects who were randomized and received at least 1 dose of investigational product. Here, N (number of subject analyzed) signifies those subjects who were evaluable for this outcome measure.

End point type	Primary
----------------	---------

End point timeframe:

Week 24

End point values	Group 1: PF-06473871: (4* 5 mg/cm)	Group 1: Placebo 4* 5 mg/cm	Group 2: PF-06473871: (3* 5 mg/cm)	Group 2: Placebo 3* 5 mg/cm
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	43	43	53	53
Units: units on scale				
least squares mean (standard error)	4 (± 0.3)	4.68 (± 0.27)	4.61 (± 0.29)	4.86 (± 0.28)

Statistical analyses

Statistical analysis title	Group1: PF--06473871: 4*5 vs Placebo 4*5 mg/cm
----------------------------	--

Statistical analysis description:

A total sample size of 100 (accounting for approximately 10% drop rate) that is approximately 50 per group at one sided 0.05 level with delta of 1.5 points with standard deviation of 2 provided at least 80% power to detect a difference from placebo using a paired test. Statistical significance was tested at the two-sided significance level of 0.1, without adjusting for multiplicity.

Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	86
Analysis specification	Pre-specified
Analysis type	superiority ^[1]
P-value	= 0.0219
Method	Repeated measures model
Parameter estimate	Least Square mean difference
Point estimate	0.68
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.19
upper limit	1.16

Variability estimate	Standard error of the mean
Dispersion value	0.29

Notes:

[1] - Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF--06473871.

Statistical analysis title	Group 2: PF-06473871: 3*5 vs Placebo 3*5 mg/cm
-----------------------------------	--

Statistical analysis description:

A total sample size of 100 (accounting for approximately 10% drop rate) that is approximately 50 per group at one sided 0.05 level with delta of 1.5 points with standard deviation of 2 provided at least 80% power to detect a difference from placebo using a paired test. Statistical significance was tested at the two-sided significance level of 0.1, without adjusting for multiplicity.

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.4038
Method	Repeated measures model
Parameter estimate	Least Square mean difference
Point estimate	0.24
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.24
upper limit	0.72
Variability estimate	Standard error of the mean
Dispersion value	0.29

Secondary: Physician Scar Assessment Using Complete Patient and Observer Scar Assessment Scale (POSAS)

End point title	Physician Scar Assessment Using Complete Patient and Observer Scar Assessment Scale (POSAS)
-----------------	---

End point description:

Physician scar assessment was performed using 10-point POSAS scale. Physician rated each of the items (vascularity, pigmentation, thickness, relief, pliability, surface area and overall opinion) for a scar on a score of 1 (normal skin) to 10 (worst scar imaginable). Within subject treatment difference was assessed between the treatment regimens each subject received. Data for overall opinion scale score at Week 24 was not presented in this outcome measure because the data was reported separately under primary outcome measure 1. Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871. mITT population included all subject who were randomized and received at least 1 dose of investigational product. Here, "n"= subject who were evaluable at given time point for each arm, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 8, 11, 18, 24

End point values	Group 1: PF-06473871: (4* 5 mg/cm)	Group 1: Placebo 4* 5 mg/cm	Group 2: PF-06473871: (3* 5 mg/cm)	Group 2: Placebo 3* 5 mg/cm
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	45	45	55	55
Units: units on scale				
least squares mean (standard error)				
Vascularity: Week 8 (n=43,43,51,51)	3.63 (± 0.24)	3.51 (± 0.25)	3.95 (± 0.24)	3.79 (± 0.24)
Vascularity: Week 11 (n=43,43,52,52)	3.64 (± 0.25)	3.83 (± 0.26)	3.76 (± 0.26)	3.83 (± 0.25)
Vascularity: Week 18 (n=40,40,52,52)	3.31 (± 0.27)	3.73 (± 0.28)	3.49 (± 0.27)	3.84 (± 0.26)
Vascularity: Week 24 (n=43,43,53,53)	3.08 (± 0.27)	3.4 (± 0.28)	3.34 (± 0.27)	3.55 (± 0.27)
Pigmentation: Week 8 (n=43,43,51,51)	3.42 (± 0.23)	3.53 (± 0.23)	3.49 (± 0.2)	3.43 (± 0.19)
Pigmentation: Week 11 (n=43,43,52,52)	3.84 (± 0.27)	3.73 (± 0.27)	3.8 (± 0.23)	3.53 (± 0.22)
Pigmentation: Week 18 (n=40,40,52,52)	3.85 (± 0.29)	3.88 (± 0.29)	3.73 (± 0.24)	3.75 (± 0.23)
Pigmentation: Week 24 (n=43,43,53,53)	3.84 (± 0.29)	3.99 (± 0.29)	4.16 (± 0.25)	4.12 (± 0.24)
Thickness: Week 8 (n=43,43,51,51)	3.38 (± 0.23)	3.56 (± 0.24)	3.59 (± 0.22)	3.56 (± 0.22)
Thickness: Week 11(n=43,43,52,52)	3.58 (± 0.26)	3.98 (± 0.26)	4.01 (± 0.25)	3.82 (± 0.24)
Thickness: Week 18 (n=40,40,52,52)	3.67 (± 0.32)	4.61 (± 0.32)	4.18 (± 0.3)	4.39 (± 0.29)
Thickness: Week 24 (n=43,43,53,53)	3.9 (± 0.32)	4.58 (± 0.33)	4.63 (± 0.31)	4.77 (± 0.3)
Relief: Week 8 (n=43,43,51,51)	3.19 (± 0.23)	3.58 (± 0.24)	3.48 (± 0.24)	3.37 (± 0.22)
Relief: Week 11(n=43,43,52,52)	3.63 (± 0.26)	3.85 (± 0.27)	3.89 (± 0.27)	3.7 (± 0.25)
Relief: Week 18 (n=40,40,52,52)	3.75 (± 0.31)	4.48 (± 0.32)	3.99 (± 0.31)	4.08 (± 0.28)
Relief: Week 24 (n=43,43,53,53)	3.87 (± 0.3)	4.39 (± 0.31)	4.38 (± 0.29)	4.53 (± 0.27)
Pliability: Week 8 (n=43,43,51,51)	3.55 (± 0.25)	3.84 (± 0.24)	3.57 (± 0.22)	3.55 (± 0.21)
Pliability: Week 11(n=43,43,52,52)	3.71 (± 0.28)	4.02 (± 0.27)	4.01 (± 0.25)	3.65 (± 0.24)
Pliability: Week 18 (n=40,40,52,52)	3.46 (± 0.31)	4.19 (± 0.3)	3.86 (± 0.27)	3.84 (± 0.26)
Pliability: Week 24 (n=43,43,53,53)	3.73 (± 0.34)	4.27 (± 0.32)	4.05 (± 0.3)	4.54 (± 0.29)
Surface Area: Week 8 (n=43,43,51,51)	3.42 (± 0.25)	3.59 (± 0.23)	3.48 (± 0.22)	3.55 (± 0.21)
Surface Area: Week 11 (n=43,43,52,52)	3.55 (± 0.27)	4.06 (± 0.25)	3.91 (± 0.23)	3.76 (± 0.22)
Surface Area: Week 18 (n=40,40,52,52)	3.97 (± 0.31)	4.61 (± 0.29)	4.33 (± 0.26)	4.32 (± 0.25)
Surface Area: Week 24 (n=43,43,53,53)	4.05 (± 0.33)	4.73 (± 0.3)	4.55 (± 0.28)	4.78 (± 0.27)
Overall Opinion: Week 8 (n=43,43,51,51)	3.5 (± 0.22)	3.74 (± 0.2)	3.66 (± 0.22)	3.75 (± 0.21)
Overall Opinion: Week 11 (n=43,43,52,52)	3.82 (± 0.25)	4.05 (± 0.24)	4.13 (± 0.25)	3.91 (± 0.24)
Overall Opinion: Week 18 (n=40,40,52,52)	3.86 (± 0.29)	4.68 (± 0.27)	4.35 (± 0.28)	4.47 (± 0.27)

Statistical analyses

Statistical analysis title	Group1: PF--06473871: 4*5 vs Placebo 4*5 mg/cm
Statistical analysis description:	
Vascularity: Week 8: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871	
Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm

Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	-0.12
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.43
upper limit	0.2
Variability estimate	Standard error of the mean
Dispersion value	0.19

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
-----------------------------------	--

Statistical analysis description:

Vascularity: Week 8: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	-0.16
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.43
upper limit	0.11
Variability estimate	Standard error of the mean
Dispersion value	0.16

Statistical analysis title	Group1: PF--06473871: 4*5 vs Placebo 4*5 mg/cm
-----------------------------------	--

Statistical analysis description:

Vascularity: Week 11: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.19
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.15
upper limit	0.52

Variability estimate	Standard error of the mean
Dispersion value	0.2

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
-----------------------------------	--

Statistical analysis description:

Vascularity: Week 11: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.07
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.22
upper limit	0.36
Variability estimate	Standard error of the mean
Dispersion value	0.17

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
-----------------------------------	---

Statistical analysis description:

Vascularity: Week 18: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.42
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.07
upper limit	0.77
Variability estimate	Standard error of the mean
Dispersion value	0.21

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
-----------------------------------	--

Statistical analysis description:

Vascularity: Week 18: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.35
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.05
upper limit	0.65
Variability estimate	Standard error of the mean
Dispersion value	0.18

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
-----------------------------------	---

Statistical analysis description:

Vascularity: Week 24: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.33
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.03
upper limit	0.68
Variability estimate	Standard error of the mean
Dispersion value	0.21

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
-----------------------------------	--

Statistical analysis description:

Vascularity: Week 24: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.22

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.09
upper limit	0.52
Variability estimate	Standard error of the mean
Dispersion value	0.18

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
-----------------------------------	---

Statistical analysis description:

Pigmentation: Week 8: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.12
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.18
upper limit	0.42
Variability estimate	Standard error of the mean
Dispersion value	0.18

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
-----------------------------------	--

Statistical analysis description:

Pigmentation: Week 8: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	-0.07
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.35
upper limit	0.22
Variability estimate	Standard error of the mean
Dispersion value	0.17

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
Statistical analysis description: Pigmentation: Week 11: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871	
Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	-0.11
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.47
upper limit	0.24
Variability estimate	Standard error of the mean
Dispersion value	0.21

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
Statistical analysis description: Pigmentation: Week 11: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871	
Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	-0.27
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.6
upper limit	0.06
Variability estimate	Standard error of the mean
Dispersion value	0.2

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
Statistical analysis description: Pigmentation: Week 18: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871	
Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm

Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.03
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.35
upper limit	0.41
Variability estimate	Standard error of the mean
Dispersion value	0.23

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
-----------------------------------	--

Statistical analysis description:

Pigmentation: Week 18: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.02
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.33
upper limit	0.37
Variability estimate	Standard error of the mean
Dispersion value	0.21

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
-----------------------------------	---

Statistical analysis description:

Pigmentation: Week 24: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.14
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.24
upper limit	0.53

Variability estimate	Standard error of the mean
Dispersion value	0.23

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
-----------------------------------	--

Statistical analysis description:

Pigmentation: Week 24: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	-0.03
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.39
upper limit	0.32
Variability estimate	Standard error of the mean
Dispersion value	0.21

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
-----------------------------------	---

Statistical analysis description:

Thickness: Week 8: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.18
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.22
upper limit	0.58
Variability estimate	Standard error of the mean
Dispersion value	0.24

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
-----------------------------------	--

Statistical analysis description:

Thickness: Week 8: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	-0.03
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.42
upper limit	0.35
Variability estimate	Standard error of the mean
Dispersion value	0.23

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
-----------------------------------	---

Statistical analysis description:

Thickness: Week 11: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.05
upper limit	0.84
Variability estimate	Standard error of the mean
Dispersion value	0.27

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
-----------------------------------	--

Statistical analysis description:

Thickness: Week 11: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	-0.19

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.62
upper limit	0.23
Variability estimate	Standard error of the mean
Dispersion value	0.25

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
-----------------------------------	---

Statistical analysis description:

Thickness: Week 18: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.94
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.4
upper limit	1.49
Variability estimate	Standard error of the mean
Dispersion value	0.33

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
-----------------------------------	--

Statistical analysis description:

Thickness: Week 18: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.21
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.3
upper limit	0.72
Variability estimate	Standard error of the mean
Dispersion value	0.31

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
Statistical analysis description:	
Thickness: Week 24: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871	
Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.68
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.13
upper limit	1.24
Variability estimate	Standard error of the mean
Dispersion value	0.34

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
Statistical analysis description:	
Thickness: Week 24: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871	
Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.14
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.38
upper limit	0.67
Variability estimate	Standard error of the mean
Dispersion value	0.32

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
Statistical analysis description:	
Relief: Week 8: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871	
Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm

Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.39
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.01
upper limit	0.78
Variability estimate	Standard error of the mean
Dispersion value	0.24

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
-----------------------------------	--

Statistical analysis description:

Relief: Week 8: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	-0.11
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.5
upper limit	0.28
Variability estimate	Standard error of the mean
Dispersion value	0.23

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
-----------------------------------	---

Statistical analysis description:

Relief: Week 11: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.22
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.23
upper limit	0.67

Variability estimate	Standard error of the mean
Dispersion value	0.27

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
-----------------------------------	--

Statistical analysis description:

Relief: Week 11: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	-0.19
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.63
upper limit	0.24
Variability estimate	Standard error of the mean
Dispersion value	0.26

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
-----------------------------------	---

Statistical analysis description:

Relief: Week 18: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.74
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.21
upper limit	1.26
Variability estimate	Standard error of the mean
Dispersion value	0.31

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
-----------------------------------	--

Statistical analysis description:

Relief: Week 18: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.09
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.41
upper limit	0.59
Variability estimate	Standard error of the mean
Dispersion value	0.3

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
-----------------------------------	---

Statistical analysis description:

Relief: Week 24: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.52
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.02
upper limit	1.02
Variability estimate	Standard error of the mean
Dispersion value	0.3

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
-----------------------------------	--

Statistical analysis description:

Relief: Week 24: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.15

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.33
upper limit	0.63
Variability estimate	Standard error of the mean
Dispersion value	0.29

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
-----------------------------------	---

Statistical analysis description:

Pliability: Week 8: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.29
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.09
upper limit	0.67
Variability estimate	Standard error of the mean
Dispersion value	0.23

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
-----------------------------------	--

Statistical analysis description:

Pliability: Week 8: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	-0.03
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.39
upper limit	0.34
Variability estimate	Standard error of the mean
Dispersion value	0.22

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
Statistical analysis description:	
Pliability: Week 11: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871	
Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.31
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.12
upper limit	0.74
Variability estimate	Standard error of the mean
Dispersion value	0.26

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
Statistical analysis description:	
Pliability: Week 11: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871	
Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	-0.35
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.76
upper limit	0.05
Variability estimate	Standard error of the mean
Dispersion value	0.25

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
Statistical analysis description:	
Pliability: Week 18: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871	
Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm

Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.73
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.25
upper limit	1.2
Variability estimate	Standard error of the mean
Dispersion value	0.29

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
-----------------------------------	--

Statistical analysis description:

Pliability: Week 18: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	-0.02
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.46
upper limit	0.42
Variability estimate	Standard error of the mean
Dispersion value	0.27

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
-----------------------------------	---

Statistical analysis description:

Pliability: Week 24: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.53
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.01
upper limit	1.05

Variability estimate	Standard error of the mean
Dispersion value	0.31

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
-----------------------------------	--

Statistical analysis description:

Pliability: Week 24: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.49
Confidence interval	
level	90 %
sides	2-sided
lower limit	0
upper limit	0.98
Variability estimate	Standard error of the mean
Dispersion value	0.3

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
-----------------------------------	---

Statistical analysis description:

Surface Area: Week 8: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.17
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.29
upper limit	0.62
Variability estimate	Standard error of the mean
Dispersion value	0.27

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
-----------------------------------	--

Statistical analysis description:

Surface Area: Week 8: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.08
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.28
upper limit	0.43
Variability estimate	Standard error of the mean
Dispersion value	0.21

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
-----------------------------------	---

Statistical analysis description:

Surface Area: Week 11: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.51
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.02
upper limit	1
Variability estimate	Standard error of the mean
Dispersion value	0.3

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
-----------------------------------	--

Statistical analysis description:

Surface Area: Week 11: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	-0.15

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.53
upper limit	0.23
Variability estimate	Standard error of the mean
Dispersion value	0.23

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
-----------------------------------	---

Statistical analysis description:

Surface Area: Week 18: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.64
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.08
upper limit	1.2
Variability estimate	Standard error of the mean
Dispersion value	0.34

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
-----------------------------------	--

Statistical analysis description:

Surface Area : Week 18: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	-0.01
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.44
upper limit	0.42
Variability estimate	Standard error of the mean
Dispersion value	0.26

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
Statistical analysis description: Surface Area: Week 24: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871	
Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.69
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.09
upper limit	1.28
Variability estimate	Standard error of the mean
Dispersion value	0.36

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
Statistical analysis description: Surface Area: week 24: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871	
Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.23
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.23
upper limit	0.69
Variability estimate	Standard error of the mean
Dispersion value	0.28

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
Statistical analysis description: Overall Opinion: Week 8 A total sample size of 100 (accounting for approximately 10% drop rate) that is approximately 50 per group at one sided 0.05 level with delta of 1.5 points with standard deviation of 2 provided at least 80% power to detect a difference from placebo using a paired test. Statistical significance was tested at the two-sided significance level of 0.1, without adjusting for multiplicity.	
Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5

	mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.2778
Method	Repeated measures model
Parameter estimate	Least Square mean difference
Point estimate	0.24
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.12
upper limit	0.6
Variability estimate	Standard error of the mean
Dispersion value	0.22

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
Statistical analysis description:	
Overall Opinion: Weekl 8 A total sample size of 100 (accounting for approximately 10% drop rate) that is approximately 50 per group at one sided 0.05 level with delta of 1.5 points with standard deviation of 2 provided at least 80% power to detect a difference from placebo using a paired test. Statistical significance was tested at the two-sided significance level of 0.1, without adjusting for multiplicity.	
Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.6888
Method	Repeated measures model
Parameter estimate	Least Square mean difference
Point estimate	0.09
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.28
upper limit	0.45
Variability estimate	Standard error of the mean
Dispersion value	0.22

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
Statistical analysis description:	
Overall Opinion: Weekl 11 A total sample size of 100 (accounting for approximately 10% drop rate) that is approximately 50 per group at one sided 0.05 level with delta of 1.5 points with standard deviation of 2 provided at least 80% power to detect a difference from placebo using a paired test. Statistical significance was tested at the two-sided significance level of 0.1, without adjusting for multiplicity.	
Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm

Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.3515
Method	Repeated measures model
Parameter estimate	Least Square mean difference
Point estimate	0.23
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.18
upper limit	0.65
Variability estimate	Standard error of the mean
Dispersion value	0.25

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
-----------------------------------	--

Statistical analysis description:

Overall Opinion: Week1 11 A total sample size of 100 (accounting for approximately 10% drop rate) that is approximately 50 per group at one sided 0.05 level with delta of 1.5 points with standard deviation of 2 provided at least 80% power to detect a difference from placebo using a paired test. Statistical significance was tested at the two-sided significance level of 0.1, without adjusting for multiplicity.

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.3788
Method	Repeated measures model
Parameter estimate	Least Square mean difference
Point estimate	-0.22
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.64
upper limit	0.19
Variability estimate	Standard error of the mean
Dispersion value	0.25

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
-----------------------------------	---

Statistical analysis description:

Overall Opinion: Week1 18 A total sample size of 100 (accounting for approximately 10% drop rate) that is approximately 50 per group at one sided 0.05 level with delta of 1.5 points with standard deviation of 2 provided at least 80% power to detect a difference from placebo using a paired test. Statistical significance was tested at the two-sided significance level of 0.1, without adjusting for multiplicity.

Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
-------------------	--

Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0044
Method	Repeated measures model
Parameter estimate	Least Square mean difference
Point estimate	0.82
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.35
upper limit	1.29
Variability estimate	Standard error of the mean
Dispersion value	0.28

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
-----------------------------------	--

Statistical analysis description:

Overall Opinion: Week 18 A total sample size of 100 (accounting for approximately 10% drop rate) that is approximately 50 per group at one sided 0.05 level with delta of 1.5 points with standard deviation of 2 provided at least 80% power to detect a difference from placebo using a paired test. Statistical significance was tested at the two-sided significance level of 0.1, without adjusting for multiplicity.

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.6848
Method	Repeated measures model
Parameter estimate	Least Square mean difference
Point estimate	0.11
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.35
upper limit	0.58
Variability estimate	Standard error of the mean
Dispersion value	0.28

Secondary: Patient Global Assessment Using Overall Opinion of Patient and Observer Scar Assessment Scale (POSAS)

End point title	Patient Global Assessment Using Overall Opinion of Patient and Observer Scar Assessment Scale (POSAS)
-----------------	---

End point description:

Patient global assessment was performed using the overall opinion question of the POSAS scale. Subjects were asked to rate the severity of their scar compared to normal skin. The overall opinion scale score ranged from 1 (normal skin) to 10 (very different from normal skin). Within subject treatment difference was assessed between the treatment regimens each subject received. mITT population included all subjects who were randomized and received at least 1 dose of investigational product. Here, "n"= subjects who were evaluable at given time point for each arm, respectively.

End point type	Secondary
End point timeframe:	
Week 8, 11, 18, 24	

End point values	Group 1: PF-06473871: (4* 5 mg/cm)	Group 2: PF-06473871: (3* 5 mg/cm)	Group 1: Placebo 4* 5 mg/cm	Group 2: Placebo 3* 5 mg/cm
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	45	55	45	55
Units: units on scale				
least squares mean (standard error)				
Week 8: (n=43,43,51,51)	5.38 (± 0.33)	5.09 (± 0.32)	5.48 (± 0.31)	5.2 (± 0.29)
Week 11: (n=43,43,52,52)	5.58 (± 0.33)	4.52 (± 0.32)	5.59 (± 0.32)	4.73 (± 0.3)
Week 18: (n=40,40,52,52)	5.34 (± 0.38)	5.18 (± 0.36)	5.78 (± 0.36)	5.18 (± 0.33)
Week 24: (n=43,43,53,53)	5.65 (± 0.39)	5.33 (± 0.38)	5.94 (± 0.37)	5.15 (± 0.35)

Statistical analyses

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
Statistical analysis description:	
Week 8: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871	
Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.7552
Method	Repeated measures model
Parameter estimate	Least Square mean difference
Point estimate	0.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.44
upper limit	0.64
Variability estimate	Standard error of the mean
Dispersion value	0.32

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
Statistical analysis description:	
Week 8: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871	
Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm

Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.6605
Method	Repeated measures model
Parameter estimate	LS mean difference
Point estimate	0.11
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.3
upper limit	0.52
Variability estimate	Standard error of the mean
Dispersion value	0.25

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
-----------------------------------	---

Statistical analysis description:

Week 11: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.9842
Method	Repeated measures model
Parameter estimate	Least Square mean difference
Point estimate	0.01
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.55
upper limit	0.56
Variability estimate	Standard error of the mean
Dispersion value	0.33

Statistical analysis title	Group 2: PF-06473871: 3*5 vs Placebo 3*5 mg/cm
-----------------------------------	--

Statistical analysis description:

Week 11: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
-------------------	--

Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.401
Method	Repeated measures model
Parameter estimate	Least Square mean difference
Point estimate	0.21
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.21
upper limit	0.63
Variability estimate	Standard error of the mean
Dispersion value	0.25

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
-----------------------------------	---

Statistical analysis description:

Week 18: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.2491
Method	Repeated measures model
Parameter estimate	Least Square mean difference
Point estimate	0.44
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.19
upper limit	1.07
Variability estimate	Standard error of the mean
Dispersion value	0.38

Statistical analysis title	Group 2: PF-06473871: 3*5 vs Placebo 3*5 mg/cm
-----------------------------------	--

Statistical analysis description:

Week 18: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
-------------------	--

Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.998
Method	Repeated measures model
Parameter estimate	Least Square mean difference
Point estimate	0
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.47
upper limit	0.47
Variability estimate	Standard error of the mean
Dispersion value	0.29

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
-----------------------------------	---

Statistical analysis description:

Week 24: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.473
Method	Repeated measures model
Parameter estimate	Least Square mean difference
Point estimate	0.28
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.37
upper limit	0.93
Variability estimate	Standard error of the mean
Dispersion value	0.39

Statistical analysis title	Group 2: PF-06473871: 3*5 vs Placebo 3*5 mg/cm
-----------------------------------	--

Statistical analysis description:

Week 24: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
-------------------	--

Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.5413
Method	Repeated measures model
Parameter estimate	Least Square mean difference
Point estimate	-0.18
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.67
upper limit	0.31
Variability estimate	Standard error of the mean
Dispersion value	0.3

Secondary: Patient-Reported Scar Evaluation Questionnaire (PR-SEQ) Symptoms and Appearance Domains Score

End point title	Patient-Reported Scar Evaluation Questionnaire (PR-SEQ) Symptoms and Appearance Domains Score
-----------------	--

End point description:

PR-SEQ questionnaire consisted of 30 different attributes of scars, included following four dimensions: appearance-5 attributes, symptoms-3 attributes, bothersomeness-8 attributes, and impacts on the quality of life (physical and emotional wellbeing-14 attributes). Each question had 5 possible responses: not at all (0), slightly (1), moderately (2), very (3), and extremely (4). Subjects completed an abbreviated version, included only the Symptoms and Appearance dimensions to evaluate treatment outcomes. Each of the item scores were transformed into a 0 to 100 scale. Each domain score ranged from 0 to 100, with higher scores indicating higher severity. Subject treatment difference was assessed between the treatment regimens each subject received. mITT population included all subjects who were randomized and received at least 1 dose of investigational product. Here "n"= subjects who were evaluable at given time point for each arm, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 8, 24

End point values	Group 1: PF-06473871: (4* 5 mg/cm)	Group 2: PF-06473871: (3* 5 mg/cm)	Group 1: Placebo 4* 5 mg/cm	Group 2: Placebo 3* 5 mg/cm
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	45	55	45	55
Units: units on scale				
least squares mean (standard error)				
Appearance: Week 8: (n=43,43,53,53)	34.95 (± 2.38)	34.5 (± 2.2)	36.27 (± 2.27)	34.14 (± 2.2)
Appearance: Week 24: (n=43,43,54,54)	43.55 (± 3.32)	42.41 (± 3.04)	47.37 (± 3.16)	42.56 (± 3.04)
Symptoms: Week 8: (n=43,43,53,53)	17.89 (± 2.62)	18.46 (± 2.71)	17.19 (± 2.34)	16.92 (± 2.47)
Symptoms: Week 24: (n=43,43,54,54)	13.74 (± 2.75)	18.22 (± 2.81)	15.49 (± 2.45)	17.09 (± 2.57)

Statistical analyses

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
Statistical analysis description:	
Appearance: Week 8: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871	
Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	1.32
Confidence interval	
level	90 %
sides	2-sided
lower limit	-3.28
upper limit	5.92
Variability estimate	Standard error of the mean
Dispersion value	2.76

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
Statistical analysis description:	
Appearance: Week 8: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871	
Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS mean difference
Point estimate	-0.36
Confidence interval	
level	90 %
sides	2-sided
lower limit	-3.63
upper limit	2.91
Variability estimate	Standard error of the mean
Dispersion value	1.97

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
Statistical analysis description:	
Appearance: Week 24: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871	
Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm

Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	3.82
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.6
upper limit	10.24
Variability estimate	Standard error of the mean
Dispersion value	3.85

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
-----------------------------------	--

Statistical analysis description:

Appearance: Week 24: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.16
Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.37
upper limit	4.68
Variability estimate	Standard error of the mean
Dispersion value	2.72

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
-----------------------------------	---

Statistical analysis description:

Symptoms: Week 8: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	-0.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.34
upper limit	2.95

Variability estimate	Standard error of the mean
Dispersion value	2.19

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
-----------------------------------	--

Statistical analysis description:

Symptoms: Week 8: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	-1.54
Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.53
upper limit	1.45
Variability estimate	Standard error of the mean
Dispersion value	1.8

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
-----------------------------------	---

Statistical analysis description:

Symptoms: Week 24: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	1.75
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.07
upper limit	5.58
Variability estimate	Standard error of the mean
Dispersion value	2.3

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
-----------------------------------	--

Statistical analysis description:

Symptoms: Week 24: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	-1.13
Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.24
upper limit	1.99
Variability estimate	Standard error of the mean
Dispersion value	1.87

Secondary: Physician and Subject Photoguide Scar Assessment Scale Score

End point title	Physician and Subject Photoguide Scar Assessment Scale Score
End point description:	Physician and subjects rated severity of each scar using a photonumeric guide on a scale ranging from 1 to 5 (where 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, 5 = very severe). Within subject treatment difference was assessed between the treatment regimens each subject received. mITT population included all subjects who were randomized and received at least 1 dose of investigational product. Here, "n"= subjects who were evaluable at given time point for each arm, respectively.
End point type	Secondary
End point timeframe:	Week 8, 11, 18, 24

End point values	Group 1: PF-06473871: (4* 5 mg/cm)	Group 2: PF-06473871: (3* 5 mg/cm)	Group 1: Placebo 4* 5 mg/cm	Group 2: Placebo 3* 5 mg/cm
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	45	55	45	55
Units: units on scale				
least squares mean (standard error)				
Physician: Week 8 (n=43,43,52,52)	2.35 (± 0.15)	2.24 (± 0.16)	2.45 (± 0.14)	2.28 (± 0.14)
Physician: Week 11 (n=43,43,53,53)	2.42 (± 0.15)	2.58 (± 0.16)	2.71 (± 0.14)	2.48 (± 0.14)
Physician: Week 18 (n=40,40,53,53)	2.48 (± 0.15)	2.7 (± 0.16)	3.05 (± 0.14)	2.74 (± 0.14)
Physician: Week 24 (n=43,43,54,54)	2.6 (± 0.15)	3 (± 0.16)	3.03 (± 0.14)	3.07 (± 0.14)
Participant: Week 8 (n=43,43,52,52)	2.41 (± 0.16)	2.28 (± 0.15)	2.51 (± 0.16)	2.25 (± 0.14)
Participant: Week 11 (n=43,43,53,53)	2.65 (± 0.16)	2.48 (± 0.15)	2.66 (± 0.16)	2.56 (± 0.14)
Participant: Week 18 (n=39,39,53,53)	2.38 (± 0.16)	2.8 (± 0.15)	2.8 (± 0.17)	2.79 (± 0.14)
Participant: Week 24 (n=43,43,54,54)	2.75 (± 0.16)	2.75 (± 0.15)	2.95 (± 0.16)	2.89 (± 0.14)

Statistical analyses

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
Statistical analysis description:	
Physician: Week 8: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871	
Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.15
upper limit	0.35
Variability estimate	Standard error of the mean
Dispersion value	0.15

Statistical analysis title	Group 2: PF-06473871: 3* 5 vs Placebo 3* 5 mg/cm
Statistical analysis description:	
Physician: Week 8: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871	
Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.03
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.22
upper limit	0.29
Variability estimate	Standard error of the mean
Dispersion value	0.16

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
Statistical analysis description:	
Physician: Week 11: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871	
Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm

Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.29
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.04
upper limit	0.54
Variability estimate	Standard error of the mean
Dispersion value	0.15

Statistical analysis title	Group 2: PF-06473871: 3*5 vs Placebo 3*5 mg/cm
-----------------------------------	--

Statistical analysis description:

Physician: Week 11: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	-0.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.36
upper limit	0.15
Variability estimate	Standard error of the mean
Dispersion value	0.15

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
-----------------------------------	---

Statistical analysis description:

Physician: Week 18: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.57
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.32
upper limit	0.82

Variability estimate	Standard error of the mean
Dispersion value	0.15

Statistical analysis title	Group 2: PF-06473871: 3*5 vs Placebo 3*5 mg/cm
-----------------------------------	--

Statistical analysis description:

Physician: Week 18: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.05
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.21
upper limit	0.3
Variability estimate	Standard error of the mean
Dispersion value	0.15

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
-----------------------------------	---

Statistical analysis description:

Physician: Week 24: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.43
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.18
upper limit	0.68
Variability estimate	Standard error of the mean
Dispersion value	0.15

Statistical analysis title	Group 2: PF-06473871: 3*5 vs Placebo 3*5 mg/cm
-----------------------------------	--

Statistical analysis description:

Physician: Week 24: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.07
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.18
upper limit	0.32
Variability estimate	Standard deviation
Dispersion value	0.15

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
-----------------------------------	---

Statistical analysis description:

Participant: Week 8: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.2
upper limit	0.39
Variability estimate	Standard error of the mean
Dispersion value	0.18

Statistical analysis title	Group 2: PF-06473871: 3*5 vs Placebo 3*5 mg/cm
-----------------------------------	--

Statistical analysis description:

Participant: Week 8: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	-0.02

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.28
upper limit	0.23
Variability estimate	Standard error of the mean
Dispersion value	0.15

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
-----------------------------------	---

Statistical analysis description:

Participant: Week 11: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.29
upper limit	0.3
Variability estimate	Standard error of the mean
Dispersion value	0.18

Statistical analysis title	Group 2: PF-06473871: 3*5 vs Placebo 3*5 mg/cm
-----------------------------------	--

Statistical analysis description:

Participant: Week 11: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.07
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.18
upper limit	0.33
Variability estimate	Standard error of the mean
Dispersion value	0.15

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
Statistical analysis description:	
Participant: Week 18: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871	
Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.42
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.12
upper limit	0.72
Variability estimate	Standard error of the mean
Dispersion value	0.18

Statistical analysis title	Group 2: PF-06473871: 3*5 vs Placebo 3*5 mg/cm
Statistical analysis description:	
Participant: Week 18: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871	
Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	-0.01
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.27
upper limit	0.24
Variability estimate	Standard error of the mean
Dispersion value	0.15

Statistical analysis title	Group1: PF-06473871: 4*5 vs Placebo 4*5 mg/cm
Statistical analysis description:	
Participant: Week 24: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871	
Comparison groups	Group 1: PF-06473871: (4* 5 mg/cm) v Group 1: Placebo 4* 5 mg/cm

Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.09
upper limit	0.5
Variability estimate	Standard error of the mean
Dispersion value	0.18

Statistical analysis title	Group 2: PF-06473871: 3*5 vs Placebo 3*5 mg/cm
-----------------------------------	--

Statistical analysis description:

Participant: Week 24: Difference is calculated as Placebo minus PF-06473871. A positive difference favors PF-06473871

Comparison groups	Group 2: PF-06473871: (3* 5 mg/cm) v Group 2: Placebo 3* 5 mg/cm
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least Square mean difference
Point estimate	0.15
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.11
upper limit	0.4
Variability estimate	Standard error of the mean
Dispersion value	0.15

Other pre-specified:

Number of Subjects With Clinically Significant Vital Sign Abnormalities

End point title	Number of Subjects With Clinically Significant Vital Sign Abnormalities
-----------------	---

End point description:

Vital Sign included pulse rate, systolic blood pressure, diastolic blood pressure, and weight. Safety population included all subjects who received at least 1 dose of investigational product.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Baseline up to Week 24

End point values	PF-06473871/Plac ebo (4* 5 mg/cm)	PF-06473871/Plac ebo (3* 5 mg/cm)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	45	55		
Units: subjects	0	0		

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Number of Subjects With Abnormal Physical Examinations

End point title	Number of Subjects With Abnormal Physical Examinations			
End point description:	Physical examination included examination of skin, head, eyes, ears, nose, throat (HEENT), respiratory, cardiovascular, abdomen - liver and kidney, musculoskeletal, gastrointestinal, genitourinary, and neurological systems. Safety population included all subjects who received at least 1 dose of investigational product.			
End point type	Other pre-specified			
End point timeframe:	Baseline up to Week 24			

End point values	PF-06473871/Plac ebo (4* 5 mg/cm)	PF-06473871/Plac ebo (3* 5 mg/cm)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	45	55		
Units: subjects	0	0		

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Number of Subjects With Electrocardiogram Findings

End point title	Number of Subjects With Electrocardiogram Findings			
End point description:	Following parameters were assessed: heart rate, PR Interval, QRS Interval, QT Interval, and Fridericia's Correction Formula (QTcF) interval. Electrocardiogram Results were reported as normal, abnormal, not clinically significant (NCS) and abnormal and clinically significant (CS) as determined by investigator. Safety population included all subjects who received at least 1 dose of investigational product. Here, "n"= subjects who were evaluable at given time point for each arm, respectively.			
End point type	Other pre-specified			
End point timeframe:	Baseline, Week 11			

End point values	PF-06473871/Plac ebo (4* 5 mg/cm)	PF-06473871/Plac ebo (3* 5 mg/cm)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	45	55		
Units: subjects				
Baseline: Normal (n=45,55)	38	43		
Baseline: Abnormal, NCS (n=45,55)	7	12		
Baseline: Abnormal , CS (n=45,55)	0	0		
Week 11: Normal (n=42,53)	33	43		
Week 11: Abnormal, NCS (n=42,53)	9	10		
Week 11: Abnormal, CS (n=42,53)	0	0		

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Number of Subjects With Treatment Emergent Adverse Events (AEs) of Special Interest

End point title	Number of Subjects With Treatment Emergent Adverse Events (AEs) of Special Interest
-----------------	---

End point description:

Treatment Emergent Adverse Events (AEs) of special interest included injection site erythema, maculopapular rash, pruritus, bronchospasm, dyspnea, cough, fever and diarrhea.

Safety population included all subjects

who received at least 1 dose of investigational product. Here, "N" (number of subjects analyzed) signifies those subjects who were evaluable for this outcome measure.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Baseline up to Week 24

End point values	PF-06473871/Plac ebo (4* 5 mg/cm)	PF-06473871/Plac ebo (3* 5 mg/cm)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	45	55		
Units: subjects	3	9		

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) Related to Laboratory Abnormalities

End point title	Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) Related to Laboratory Abnormalities
-----------------	---

End point description:

An adverse event (AE) was any untoward medical occurrence in a subjects who received study drug without regard to possibility of causal relationship. Treatment-emergent adverse event are events between first dose of study drug and up to Week 24 that were absent before treatment or that worsened relative to pre-treatment state. TEAEs related to laboratory abnormalities are reported.

Safety population included all subjects who received at least 1 dose of investigational product.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Baseline up to Week 24

End point values	PF-06473871/Plac ebo (4* 5 mg/cm)	PF-06473871/Plac ebo (3* 5 mg/cm)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	45	55		
Units: subjects				
Leukopenia	0	1		
Hyperbilirubinemia	0	1		
Amylase increased	1	1		
Blood creatine phosphokinase (CPK) increased	2	6		
Blood glucose increased	0	1		
Blood lactate dehydrogenase (LDH) increased	0	1		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Baseline up to Week 24

Adverse event reporting additional description:

There was no overall separate placebo group for safety assessment as each subject received both placebo as well as active drug. AE assessment was done between those who received 3 versus 4 doses of active drug.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	15.1
--------------------	------

Reporting groups

Reporting group title	PF-06473871/Placebo (4* 5 mg/cm)
-----------------------	----------------------------------

Reporting group description:

Subjects with bilateral hypertrophic scars received 4 intradermal injections of PF-06473871 at a dose of 5 mg/cm (2.5 mg on each side of the revised scar) on one breast at Week 2, 5, 8 and 11; and 4 intradermal injections of placebo matched to PF-06473871 at Week 2, 5, 8 and 11 on another breast.

Reporting group title	PF-06473871/Placebo (3* 5 mg/cm)
-----------------------	----------------------------------

Reporting group description:

Subjects with bilateral hypertrophic scars received 3 intradermal injections of PF-06473871 at a dose of 5 mg/cm (2.5 mg on each side of the revised scar) on one breast at Week 2, 5 and 8; and 3 intradermal injections of placebo matched to PF-06473871 at Week 2, 5 and 8 on another breast.

Serious adverse events	PF-06473871/Placebo (4* 5 mg/cm)	PF-06473871/Placebo (3* 5 mg/cm)	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 45 (0.00%)	0 / 55 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	PF-06473871/Placebo (4* 5 mg/cm)	PF-06473871/Placebo (3* 5 mg/cm)	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	30 / 45 (66.67%)	35 / 55 (63.64%)	
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 45 (0.00%)	2 / 55 (3.64%)	
occurrences (all)	0	2	

General disorders and administration site conditions			
Injection site erythema			
subjects affected / exposed	3 / 45 (6.67%)	5 / 55 (9.09%)	
occurrences (all)	3	5	
Injection site pain			
subjects affected / exposed	10 / 45 (22.22%)	9 / 55 (16.36%)	
occurrences (all)	10	9	
Injection site pruritus			
subjects affected / exposed	3 / 45 (6.67%)	4 / 55 (7.27%)	
occurrences (all)	3	4	
Application site rash			
subjects affected / exposed	0 / 45 (0.00%)	1 / 55 (1.82%)	
occurrences (all)	0	1	
Injection site rash			
subjects affected / exposed	1 / 45 (2.22%)	0 / 55 (0.00%)	
occurrences (all)	1	0	
Injection site reaction			
subjects affected / exposed	0 / 45 (0.00%)	1 / 55 (1.82%)	
occurrences (all)	0	1	
Injection site urticaria			
subjects affected / exposed	1 / 45 (2.22%)	0 / 55 (0.00%)	
occurrences (all)	1	0	
Oedema peripheral			
subjects affected / exposed	1 / 45 (2.22%)	0 / 55 (0.00%)	
occurrences (all)	1	0	
Pyrexia			
subjects affected / exposed	0 / 45 (0.00%)	1 / 55 (1.82%)	
occurrences (all)	0	1	
Social circumstances			
Treatment noncompliance			
subjects affected / exposed	0 / 45 (0.00%)	1 / 55 (1.82%)	
occurrences (all)	0	1	
Reproductive system and breast disorders			
Dysmenorrhoea			
subjects affected / exposed	0 / 45 (0.00%)	1 / 55 (1.82%)	
occurrences (all)	0	1	

Breast haematoma subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	1 / 55 (1.82%) 1	
Breast mass subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	1 / 55 (1.82%) 1	
Menstruation irregular subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	1 / 55 (1.82%) 1	
Respiratory, thoracic and mediastinal disorders			
Oropharyngeal pain subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	1 / 55 (1.82%) 1	
Rhinitis allergic subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	0 / 55 (0.00%) 0	
Psychiatric disorders			
Anxiety subjects affected / exposed occurrences (all)	2 / 45 (4.44%) 2	1 / 55 (1.82%) 1	
Insomnia subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	1 / 55 (1.82%) 1	
Investigations			
Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)	2 / 45 (4.44%) 2	6 / 55 (10.91%) 6	
Amylase increased subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	1 / 55 (1.82%) 1	
Blood glucose increased subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	1 / 55 (1.82%) 1	
Blood lactate dehydrogenase increased			

subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	1 / 55 (1.82%) 1	
Weight increased subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	0 / 55 (0.00%) 0	
Injury, poisoning and procedural complications			
Incision site pain subjects affected / exposed occurrences (all)	5 / 45 (11.11%) 5	4 / 55 (7.27%) 4	
Wound dehiscence subjects affected / exposed occurrences (all)	4 / 45 (8.89%) 4	0 / 55 (0.00%) 0	
Incision site pruritus subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	2 / 55 (3.64%) 2	
Procedural site reaction subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	1 / 55 (1.82%) 1	
Ankle fracture subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	0 / 55 (0.00%) 0	
Burns second degree subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	0 / 55 (0.00%) 0	
Incision site complication subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	0 / 55 (0.00%) 0	
Ligament sprain subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	1 / 55 (1.82%) 1	
Post procedural swelling subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	1 / 55 (1.82%) 1	
Procedural headache			

subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	0 / 55 (0.00%) 0	
Procedural nausea subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	1 / 55 (1.82%) 1	
Procedural vomiting subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	1 / 55 (1.82%) 1	
Spinal compression fracture subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	0 / 55 (0.00%) 0	
Suture rupture subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	0 / 55 (0.00%) 0	
Cardiac disorders Palpitations subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	1 / 55 (1.82%) 1	
Nervous system disorders Headache subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	2 / 55 (3.64%) 2	
Paraesthesia subjects affected / exposed occurrences (all)	2 / 45 (4.44%) 2	0 / 55 (0.00%) 0	
Hyperaesthesia subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	1 / 55 (1.82%) 1	
Neuralgia subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	1 / 55 (1.82%) 1	
Piriformis syndrome subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	1 / 55 (1.82%) 1	
Blood and lymphatic system disorders			

Leukopenia subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	1 / 55 (1.82%) 1	
Ear and labyrinth disorders Motion sickness subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	1 / 55 (1.82%) 1	
Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all) Constipation subjects affected / exposed occurrences (all) Abdominal pain upper subjects affected / exposed occurrences (all) Gastritis subjects affected / exposed occurrences (all) Gingival pain subjects affected / exposed occurrences (all) Toothache subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0 1 / 45 (2.22%) 1 0 / 45 (0.00%) 0 0 / 45 (0.00%) 0 0 / 45 (0.00%) 0 0 / 45 (0.00%) 0 0 / 45 (0.00%) 0	4 / 55 (7.27%) 4 1 / 55 (1.82%) 1 1 / 55 (1.82%) 1 1 / 55 (1.82%) 1 1 / 55 (1.82%) 1 1 / 55 (1.82%) 1	
Hepatobiliary disorders Hyperbilirubinaemia subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	1 / 55 (1.82%) 1	
Skin and subcutaneous tissue disorders Pruritus subjects affected / exposed occurrences (all) Scar pain subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0 1 / 45 (2.22%) 1	1 / 55 (1.82%) 1 2 / 55 (3.64%) 2	

Itching scar subjects affected / exposed occurrences (all)	2 / 45 (4.44%) 2	0 / 55 (0.00%) 0	
Acne subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	0 / 55 (0.00%) 0	
Dermatitis contact subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	0 / 55 (0.00%) 0	
Urticaria subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	0 / 55 (0.00%) 0	
Musculoskeletal and connective tissue disorders			
Back pain subjects affected / exposed occurrences (all)	2 / 45 (4.44%) 2	0 / 55 (0.00%) 0	
Osteoarthritis subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	1 / 55 (1.82%) 1	
Pain in jaw subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	1 / 55 (1.82%) 1	
Infections and infestations			
Upper respiratory tract infection subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	2 / 55 (3.64%) 2	
Influenza subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	2 / 55 (3.64%) 2	
Nasopharyngitis subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	1 / 55 (1.82%) 1	
Sinusitis subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	1 / 55 (1.82%) 1	
Bronchitis			

subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	0 / 55 (0.00%) 0	
Acute sinusitis subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	0 / 55 (0.00%) 0	
Cellulitis subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	0 / 55 (0.00%) 0	
Fungal infection subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	1 / 55 (1.82%) 1	
Tooth infection subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	1 / 55 (1.82%) 1	
Urinary tract infection subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	0 / 55 (0.00%) 0	
Vaginal infection subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	0 / 55 (0.00%) 0	
Viral rhinitis subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	0 / 55 (0.00%) 0	
Metabolism and nutrition disorders			
Folate deficiency subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	0 / 55 (0.00%) 0	
Vitamin D deficiency subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	0 / 55 (0.00%) 0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported